Joe Odell·January 5, 2026

Complexity Hides Fragility: Losing a $20m Business | Joe Odell Interview

Joe Odell, an enlisted military veteran turned Berkeley MBA graduate, partnered with classmate Jess Patterson to conduct a traditional search fund, raising $800k from ~24 investors and acquiring Pharmacy Specialist, a $20m-revenue home infusion pharmacy (IVIG, antibiotic, and cardiology IV drugs) in the Dallas-Houston area for roughly $26m (6.5x EBITDA) with ~$16m in debt. The first year was a near-death experience: a pre-close non-disclosure (a key sales rep departure that erased 20% of revenue), January insurance recertification cash crunches, duplicated patient records masking real flat growth, and a drug reimbursement error all hit simultaneously. Joe and Jess stabilized by Q4 of year one, reaching $4m EBITDA run rate again. In year two, the primary cardiology drug manufacturer slashed its AWP by ~90% — an unprecedented event that vaporized $2m of EBITDA overnight, leaving the business unable to service its $200k/month debt load. After 18 more months of fighting, two rounds of layoffs, closing the Houston office, and running on fumes, Joe convened the board, told investors he could not in good conscience take more capital, and handed the business back to the bank. The core lesson: complexity amplifies every risk and demands deep industry expertise; the debt load that made the returns look great on a model is exactly what makes a stressed business unrecoverable. Joe has since acquired a small plumbing company for $50k ($10k down, seller note) and tripled its revenue to a ~$1.5m run rate within eight months while consulting part-time.

Deal facts

purchase price: ~$26m (6.5x multiple on ~$4m EBITDA)
multiple: 6.5x EBITDA
sde ebitda: EBITDA ~$4m (just over 20% of $20m revenue)
revenue: $20m
financing structure: 3x traditional debt + ~1.5x seller note + 2x equity; ~$16m in total debt; traditional search fund structure with ~$800k raised from ~24 investors
notes: Seller retained small equity stake (slightly under 10%) and stayed on in an operations role through the end of the first full year. The $250,000 Marwood healthcare diligence study was required by the lender and came out of the $800k search fund raise. Business ultimately failed and was handed back to the bank after ~2.5 years of operation. Joe and Jess had no personal guarantee on the SBA-style conventional debt.

Why this business

Joe and his partner Jess were attracted to home health-adjacent businesses riding the post-COVID tailwind of aging population and Congressional moves expanding Medicare home health access. They wanted picks-and-shovels exposure to home health without being directly patient-facing as operators. The home infusion pharmacy fit the thesis: life-preserving prescriptions (high quality of revenue), 20%+ EBITDA margins, two years of 20% growth, and an $4m EBITDA base that could arbitrage multiple expansion if grown to $5-7m. The seller also wanted to stay on in an operations role, easing transition risk.

What's working

Business rebounded strongly in Q3-Q4 of the first year after three simultaneous early crises; Q4 first year hit a $1m EBITDA run rate, proving the underlying business had real demand
Joe caught a drug reimbursement error (daptomycin AWP miscalculation) early on and fixed it, improving profitability
Joe and Jess maintained a complementary division of labor under pressure: Jess focused on cash and cost control, Joe on revenue and growth; both stayed aligned throughout
Despite all difficulties, the company still did over $20m in sales in each of the first two full operating years
Joe spun up a new IVIG and specialty medication growth focus to offset the cardiology revenue collapse
After the business closed, Joe immediately landed consulting gigs with board portfolio companies and replaced his CEO salary within two weeks
Separately from the pharmacy failure, Joe acquired a small plumbing business for ~$50k ($10k down, rest seller note) and tripled revenue to a ~$1.5m run rate within 8 months with minimal involvement

What's hard

A key sales rep departed before close — a non-disclosed event that wiped approximately 20% of revenue in the first three months
January insurance recertification (prior authorization resets) caused a severe cash crunch in the first month
Duplicate patient records across two locations (Dallas and Houston) inflated the patient census, masking actual flat-to-declining growth
A drug reimbursement error on daptomycin further compressed margins from day one
In year two, the manufacturer of the primary cardiology drug cut its AWP (average wholesale price) by ~90%, eliminating $2m of EBITDA overnight — an unprecedented and unforeseeable event
Heavy debt load (~$16m, ~$200k/month in service payments) made the business impossible to survive even at breakeven operations; if there had been no debt, the business would likely have survived
Two rounds of layoffs cut the company from 100 to ~20 employees; shutting the Houston location was extremely painful
The Marwood healthcare diligence study cost $250k out of an $800k search fund — leaving limited working capital at close
Started with just under $2m in working capital, which proved insufficient; Joe's lesson: whatever you think you need, double it
Post-closure, Jess had a CFO offer rescinded by a search-fund-backed acquirer after an unnamed board member spread negative impressions of the deal's outcome — a painful injustice Joe felt strongly about correcting publicly
Complexity in the healthcare/pharmacy industry — payer relationships, drug concentration, manufacturer pricing power — requires deep industry experience that a generalist searcher is unlikely to have

Notable quotes

I think a really boring business is very attractive at this point because I went with really complicated and complication costs you a lot of brain power and just is a whole another risk on top of everything else.

One of the lies that we told ourselves when we started our search was that there's a lot of money being made in complicated businesses. And although that can be true, that's not always true. And what complicated businesses are just like debt, yes, there's a moat, but there's also a ton of risk just like debt, right? It just means you're closer to the knife's edge.

I just sat there and I'm like we never took another, you know, other than the first deal when we raised the capital. We never did another turn of the hat, another capital call, anything like that. And so this is our second capital call now. It's been two and a half years. And I just had this pit in my stomach like I can't take another dime.

I got the board together the next day and just said, 'Hey, this is what I'm seeing and I do not feel like your money's safe.' I feel like if you put money into this business, you're going to lose it. And so we made the call to close the doors at that point.